Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
NovaBay anounces details of dermatology program
Emeryville, Calif. - NovaBay Parmaceuticals announces it has successfully developed several formulations of Agonocide compounds for use in dermatology.
Emeryville, Calif.
- NovaBay Parmaceuticals announces it has successfully developed several formulations of Agonocide compounds for use in dermatology, according to iStockAnalysis.com.
One formulations, AgaDerm, delivers an Aganocide compound effectively when applied on the surface of the skin, and furthered penetration into hair follicles to treat fungal infections.
Related Videos
Related Content
